share_log

United Therapeutics | 8-K: United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

United Therapeutics | 8-K: United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

美国联合医疗 | 8-K：联合疗法公司公布2024年第三季度财务业绩
美股SEC公告 ·  2024/10/30 03:37

Moomoo AI 已提取核心信息

United Therapeutics reported robust Q3 2024 financial results with total revenues increasing 23% YoY to $748.9 million, driven by a 33% growth in Tyvaso product line to $433.8 million. Net income rose 16% to $309.1 million, with earnings per diluted share of $6.39. The company achieved record revenue for the sixth consecutive quarter, marking a $3 billion annual revenue run rate.Tyvaso DPI led the growth with $274.6 million in sales, up 34% YoY, while nebulized Tyvaso contributed $159.2 million, up 32%. Orenitram and Unituxin also showed strong performance with 23% and 19% growth respectively. The growth was primarily attributed to increased patient utilization and strategic price adjustments.The company anticipates multiple clinical milestones in 2025, including data readouts from TETON studies in idiopathic pulmonary fibrosis, ADVANCE OUTCOMES in pulmonary arterial hypertension, and the miroliverELAP phase 1 study. Additionally, United Therapeutics plans to file an investigational new drug application for its UKidney human clinical program.
United Therapeutics reported robust Q3 2024 financial results with total revenues increasing 23% YoY to $748.9 million, driven by a 33% growth in Tyvaso product line to $433.8 million. Net income rose 16% to $309.1 million, with earnings per diluted share of $6.39. The company achieved record revenue for the sixth consecutive quarter, marking a $3 billion annual revenue run rate.Tyvaso DPI led the growth with $274.6 million in sales, up 34% YoY, while nebulized Tyvaso contributed $159.2 million, up 32%. Orenitram and Unituxin also showed strong performance with 23% and 19% growth respectively. The growth was primarily attributed to increased patient utilization and strategic price adjustments.The company anticipates multiple clinical milestones in 2025, including data readouts from TETON studies in idiopathic pulmonary fibrosis, ADVANCE OUTCOMES in pulmonary arterial hypertension, and the miroliverELAP phase 1 study. Additionally, United Therapeutics plans to file an investigational new drug application for its UKidney human clinical program.
美国联合医疗发布了2024年第三季度强劲的财务业绩，总营业收入同比增长23%，达到74890万美元，主要受益于Tyvaso产品线增长33%，达到43380万美元。净利润增长16%，达到30910万美元，每股摊薄收益为6.39美元。该公司连续第六个季度实现创纪录的营业收入，年营业收入运行率达到30亿美元。Tyvaso DPI以27460万美元的销售额引领增长，同比增长34%；而雾化Tyvaso贡献了15920万美元，同比增长32%。Orenitram和Unituxin也表现强劲，分别增长23%和19%。这一增长主要归因于患者利用率的增加和战略性价格调整。该公司预计在2025年会有多个临床里程碑，包括特发性肺纤维化的TETON研究数据公布、肺动脉高压的ADVANCE OUTCOMES和miroliverELAP第1期研究。此外，美国联合医疗计划为其UKidney人类临床项目提交一项研究新药申请。
美国联合医疗发布了2024年第三季度强劲的财务业绩，总营业收入同比增长23%，达到74890万美元，主要受益于Tyvaso产品线增长33%，达到43380万美元。净利润增长16%，达到30910万美元，每股摊薄收益为6.39美元。该公司连续第六个季度实现创纪录的营业收入，年营业收入运行率达到30亿美元。Tyvaso DPI以27460万美元的销售额引领增长，同比增长34%；而雾化Tyvaso贡献了15920万美元，同比增长32%。Orenitram和Unituxin也表现强劲，分别增长23%和19%。这一增长主要归因于患者利用率的增加和战略性价格调整。该公司预计在2025年会有多个临床里程碑，包括特发性肺纤维化的TETON研究数据公布、肺动脉高压的ADVANCE OUTCOMES和miroliverELAP第1期研究。此外，美国联合医疗计划为其UKidney人类临床项目提交一项研究新药申请。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间